Authors

• Koichiro Watanabe (ORCID: https://orcid.org/0000-0002-0736-7070)
• Hiroyuki Muraoka (ORCID: https://orcid.org/0000-0002-6728-5341)
• Yoshiteru Takekita (ORCID: https://orcid.org/0000-0003-2435-4033)
• Michinori Koebis (ORCID: https://orcid.org/0000-0002-6451-3409)
• Masahiro Takeshima (ORCID: https://orcid.org/0000-0003-0614-7524)
• Ken Inada (ORCID: https://orcid.org/0000-0002-3073-4588)
• Motohiro Ozone (ORCID: https://orcid.org/0000-0003-1738-3629)
• Masaki Kato (ORCID: https://orcid.org/0000-0001-6727-7272)
• Takeshi Terao (ORCID: https://orcid.org/0000-0001-7545-4304)
• Yosuke Koshikawa (ORCID: https://orcid.org/0000-0002-6736-092X)
• Yoshikazu Takaesu (ORCID: https://orcid.org/0000-0002-9169-3249)
• Hikaru Hori (ORCID: https://orcid.org/0000-0001-8179-3054)
• Hirofumi Hirakawa (ORCID: https://orcid.org/0000-0002-7782-5807)
• Hitoshi Sakurai (ORCID: https://orcid.org/0000-0002-5399-7946)
• Tomohiko Murao
• Yuka Kawatsu (ORCID: https://orcid.org/0009-0002-7836-611X)
• Haruka Yokoyama

Institutions

• Kurume University (JP)
• Kansai Medical University (JP)
• Oita University (JP)
• Kyorin University (JP)
• Akita University (JP)
• Fukuoka University (JP)
• University of the Ryukyus (JP)
• Minamiaoyama Eye Clinic (JP)
• Eisai (Japan) (JP)
• Kitasato University (JP)

Publication Details

Journal

CNS Drugs

Published

2025-12-04

DOI

https://doi.org/10.1007/s40263-025-01245-w

Primary Topic

Sleep and related disorders

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Eli Lilly and Company
• Pfizer
• EA Pharma Co., Ltd.
• Kowa Company
• Boehringer Ingelheim Japan
• Nipro
• Eisai
• Meiji Seika Pharma
• Shionogi
• Otsuka Pharmaceutical
• Teijin Pharma
• Mitsubishi Tanabe Pharma Corporation
• Ono Pharmaceutical
• H. Lundbeck A/S
• Novartis Pharma
• Pfizer Japan
• Eli Lilly Japan
• Japan Society for the Promotion of Science
• Daiichi Sankyo Europe